Monopar Therapeutics (MNPR) stock
MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$71.06−0.91 (-1.26%)
Close on Nov 17, 2026Market cap $476.97MP/E –Yield –
Monopar Therapeutics cash
Cash and short-term investments held at the end of each period.
Monopar Therapeutics's cash was $105.37M at Jun 30, 2026. For fiscal 2025 it was $122.71M, up 34.3% from the year before. Over ten years it grew 45.9% a year on average. The highest annual figure on record is $122.71M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.71M | +34.3% |
| FY2024 | Dec 31, 2024 | $91.35M | +561.4% |
| FY2023 | Dec 31, 2023 | $13.81M | +13.4% |
| FY2022 | Dec 31, 2022 | $12.18M | -39.1% |
| FY2021 | Dec 31, 2021 | $20.01M | +19.6% |
| FY2020 | Dec 31, 2020 | $16.74M | +26.7% |
| FY2019 | Dec 31, 2019 | $13.21M | +91.7% |
| FY2018 | Dec 31, 2018 | $6.89M | -29.5% |
| FY2017 | Dec 31, 2017 | $9.78M | +240.5% |
| FY2016 | Dec 31, 2016 | $2.87M | +2.4% |
| FY2015 | Dec 31, 2015 | $2.81M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $105.37M | +33.7% |
| Q1 FY2026 | Mar 31, 2026 | $104.91M | +32.4% |
| Q4 FY2025 | Dec 31, 2025 | $122.71M | +34.3% |
| Q3 FY2025 | Sep 30, 2025 | $255.17M | +2059.6% |
| Q2 FY2025 | Jun 30, 2025 | $78.83M | +506.5% |
| Q1 FY2025 | Mar 31, 2025 | $79.23M | +394.4% |
| Q4 FY2024 | Dec 31, 2024 | $91.35M | +561.4% |
| Q3 FY2024 | Sep 30, 2024 | $11.82M | -10.3% |
| Q2 FY2024 | Jun 30, 2024 | $13.00M | -20.4% |
| Q1 FY2024 | Mar 31, 2024 | $16.03M | +53.8% |
| Q4 FY2023 | Dec 31, 2023 | $13.81M | +13.4% |
| Q3 FY2023 | Sep 30, 2023 | $13.17M | -8.0% |
| Q2 FY2023 | Jun 30, 2023 | $16.33M | -0.8% |
| Q1 FY2023 | Mar 31, 2023 | $10.42M | -41.5% |
| Q4 FY2022 | Dec 31, 2022 | $12.18M | -39.1% |
| Q3 FY2022 | Sep 30, 2022 | $14.32M | -35.9% |
| Q2 FY2022 | Jun 30, 2022 | $16.46M | -32.2% |
| Q1 FY2022 | Mar 31, 2022 | $17.82M | -30.7% |
| Q4 FY2021 | Dec 31, 2021 | $20.01M | +19.6% |
| Q3 FY2021 | Sep 30, 2021 | $22.34M | +24.2% |
| Q2 FY2021 | Jun 30, 2021 | $24.29M | +93.6% |
| Q1 FY2021 | Mar 31, 2021 | $25.72M | +104.3% |
| Q4 FY2020 | Dec 31, 2020 | $16.74M | +26.7% |
| Q3 FY2020 | Sep 30, 2020 | $17.98M | +300.1% |
| Q2 FY2020 | Jun 30, 2020 | $12.55M | +144.6% |
| Q1 FY2020 | Mar 31, 2020 | $12.59M | +114.1% |
| Q4 FY2019 | Dec 31, 2019 | $13.21M | +91.7% |
| Q3 FY2019 | Sep 30, 2019 | $4.49M | -41.0% |
| Q2 FY2019 | Jun 30, 2019 | $5.13M | -37.6% |
| Q1 FY2019 | Mar 31, 2019 | $5.88M | -34.5% |
| Q4 FY2018 | Dec 31, 2018 | $6.89M | -29.5% |
| Q3 FY2018 | Sep 30, 2018 | $7.62M | -28.0% |
| Q2 FY2018 | Jun 30, 2018 | $8.22M | +92.0% |
| Q1 FY2018 | Mar 31, 2018 | $8.97M | +152.7% |
| Q4 FY2017 | Dec 31, 2017 | $9.78M | +240.5% |
| Q3 FY2017 | Sep 30, 2017 | $10.59M | +277.4% |
| Q2 FY2017 | Jun 30, 2017 | $4.28M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.87M | – |
| Q4 FY2015 | Dec 31, 2015 | $2.81M | – |
See a number that looks wrong?